MedTrace Logo

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

NCT04675242 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2023-06-18

Study results available
· View outcomes & findings →

Summary

This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.

Conditions

  • Blepharitis

Interventions

DRUG

NCX 4251

NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily

DRUG

Placebo

Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily

Sponsors & Collaborators

  • Nicox Ophthalmics, Inc.

    lead INDUSTRY

Principal Investigators

  • Nicox Ophthalmics · Nicox Ophthalmics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2021-06-16
Completion
2021-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04675242 on ClinicalTrials.gov